Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial.
about
A novel approach in the treatment of neuroendocrine gastrointestinal tumors: additive antiproliferative effects of interferon-gamma and meta-iodobenzylguanidinerIFN-gamma-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibitionTrial watch: IDO inhibitors in cancer therapyThe indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cellsEffect of plasmid-mediated stable interferon-γ expression on proliferation and cell death in the SKOV-3 human ovarian cancer cell line.Interferons and interferon regulatory factors in malariaThe class II tumour suppressor gene H-REV107-1 is a target of interferon-regulatory factor-1 and is involved in IFNgamma-induced cell death in human ovarian carcinoma cells.PEGylation improves the pharmacokinetic properties and ability of interferon gamma to inhibit growth of a human tumor xenograft in athymic mice.Neuropharmacology of N,N-dimethyltryptamineAdenovirus-mediated delivery of interferon-γ gene inhibits the growth of nasopharyngeal carcinomaImmune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin.Tregs and rethinking cancer immunotherapy.A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer.Role of chemotherapy in the management of ovarian cancer.Differential expression of IL-17, 22 and 23 in the progression of colorectal cancer in patients with K-ras mutation: Ras signal inhibition and crosstalk with GM-CSF and IFN-γThe combination of chemotherapy and systemic immunotherapy and the concept of cure in murine leukemia and lymphoma.The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.Immunotherapy for ovarian cancer.IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.Novel therapies for recurrent ovarian cancer management.Association between interferon gamma 13-CA-repeats polymorphism and metastasis of nasopharyngeal carcinoma in a population of Northern China.First-line therapy for ovarian carcinoma: what's next?Novel agents in epithelial ovarian cancer.Targeted therapy for epithelial ovarian cancer.Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients.Immunotherapy for gynaecological malignancies.Investigational agents for epithelial ovarian cancer.Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients.Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study.S-nitrosylation of ERK inhibits ERK phosphorylation and induces apoptosisOpportunities in immunotherapy of ovarian cancer.Novel agents in ovarian cancer.Immunotherapy opportunities in ovarian cancer.The impact of T-cell immunity on ovarian cancer outcomes.Adenoviral vector-based strategies for cancer therapy.Cancer immunotherapy and nanomedicine.Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance.Immune therapy for ovarian cancer: promise and pitfalls.A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity.
P2860
Q24799372-2ED4A43A-7FF6-45FF-8B74-BE125731B2B4Q24805224-7DB1C303-D78E-4526-BF59-78FD792936DFQ27006866-5B2FDF15-1D05-46F8-AE7D-1B70A168A35FQ28744405-1A99EE31-209B-4BB0-A29C-B9DA10D7DF1BQ33791134-437EB942-D763-4967-A14E-1BF5C2F6E2A0Q34012443-A1375813-CE4B-4091-95AC-3A4EEF9727AEQ34125310-2E24F5D6-DBD0-413F-9FEA-C68541533B77Q34294045-00A07CEF-E9C5-4CF9-8364-11E81C2D726BQ34524116-D48FC5FA-C875-4F4D-8A62-8F63FD271B37Q34526425-2E78F48B-FDA9-4E24-B1FA-254312819C74Q34557233-70F71D94-2732-41D9-8C5D-288B495672BDQ34590873-8220750F-6646-4F9C-A0BE-1D585BB3D560Q34625147-1B584D53-868F-446C-B0F8-669A25858342Q34667823-2943AF18-69F8-49F1-80AE-E6DD4BCD2807Q34734126-650892EF-2A6E-4105-A5F5-10CAABA60AE2Q34989005-8648C6AC-F959-444F-A243-82D3F9CF3637Q35047632-371C627B-B9C8-4DEC-92DF-973ABDC9FC30Q35058213-7541CA36-6D3F-4661-B311-259835EF614BQ35164189-ACB19BED-C6B5-4C5F-A3F6-44CCB2B7BC01Q35677893-64B32EF3-7416-49E0-A430-A6FD98F6F362Q35782940-D4E7EB79-CC46-4F7E-B6E6-04CDC69B9717Q35919485-35C1CAD2-CDD3-4B51-8DBB-4539AD01610EQ35968748-27D10B51-F65C-42FF-A185-4D65DE69B87DQ35968752-52FF6441-3281-43E7-A401-A6346D9C4E30Q36158708-58661272-1FD3-45BA-941E-A88DDA6C6BA8Q36198776-5B7627C8-9A7D-41EB-8F83-3EDB28F82DA4Q36239661-C76968D2-EFFF-4B2D-9580-33661667A6C9Q36284514-57E56E06-5333-4A3D-AB4D-3BBFB701AAD1Q36317366-DA569B3F-5E6A-46A3-95B0-03C4F4D2E9E6Q36626046-662BED2C-6C21-4499-918F-72F3905C77B8Q36828963-BF199A21-FDD6-436D-9760-DCB7E3ADE134Q36855245-6FBB4CFD-3B94-4589-B7F5-9A96E7E4F28EQ36904860-D1A2D347-DC88-47FD-9866-A526C28C0138Q37086013-E10D6BC8-14FC-46B0-AA46-493547912580Q37118142-EC888A64-1F91-4633-A565-2ED64A5F5FA4Q37409025-C46935B3-527F-4297-8511-85AE4B0ED8BBQ37785836-CB7503E0-46A7-4FBA-980A-7A1540B52EFAQ37836612-F3B128B6-E24E-493E-B7B4-890F2D5546C0Q37873928-34E5D7C5-4230-4013-989E-7791DFD05850Q38101865-3F91C5A2-4B50-48A8-A890-41D47C44BD5D
P2860
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Interferon-gamma in the first- ...... a randomized phase III trial.
@ast
Interferon-gamma in the first- ...... a randomized phase III trial.
@en
type
label
Interferon-gamma in the first- ...... a randomized phase III trial.
@ast
Interferon-gamma in the first- ...... a randomized phase III trial.
@en
prefLabel
Interferon-gamma in the first- ...... a randomized phase III trial.
@ast
Interferon-gamma in the first- ...... a randomized phase III trial.
@en
P2093
P2860
P356
P1476
Interferon-gamma in the first- ...... a randomized phase III trial.
@en
P2093
Hausmaninger H
Müller-Holzner E
Stummvoll W
Windbichler GH
P2860
P2888
P304
P356
10.1054/BJOC.1999.1053
P407
P577
2000-03-01T00:00:00Z
P5875
P6179
1003625003